구조모아 (StructureMoa)항암 chemical structure spider web
방문Allife Medical ScienceTechnology Co.Ltd.
CRISPR/Cas9(Allife Medical Science and Technology Co., Ltd.)은 Human Papillomavirus-Related Malignant N 표적 세포·유전자 치료로, Human Papillomavirus-Related Malignant Neoplasm 영역에서 개발·상용화 중입니다. 작용기전: targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinato. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 25% (ClinicalTrials.gov NCT04035434). 차별점: novel link between intracellular cholesterol metabolism and vascular growth.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Human Papillomavirus-Related Malignant N
Human Papillomavirus-Related Malignant Neoplasm
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
CAR-T engineering for colorectal cancer: integrating targets, tum
retroviral therapies suppress HIV replication but fail to eliminate integrated proviral DN
humanized mice, CD4-NBs significantly reduced plasma viremia
novel link between intracellular cholesterol metabolism and vascular growth
targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen
macrophages, we engineered a novel trispecific macrophage engager (TriME) designed for simultaneous engagement
payloads and remodel the tumor microenvironment; in infectious diseases, they enhance pathogen clearance; and in autoimmune dis
PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression
resistance to GA-DM, disruption of genes involved in ubiquitin-mediated proteolysis and the Hippo pathway sensitised cells to GA-DM
구조화 데이터
syngeneic murine model
mouse, mouse
PK
IC50 585
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Allife Medical ScienceTechnology Co.Ltd.
CRISPR/Cas9(Allife Medical Science and Technology Co., Ltd.)은 Human Papillomavirus-Related Malignant N 표적 세포·유전자 치료로, Human Papillomavirus-Related Malignant Neoplasm 영역에서 개발·상용화 중입니다. 작용기전: targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinato. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 25% (ClinicalTrials.gov NCT04035434). 차별점: novel link between intracellular cholesterol metabolism and vascular growth.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Human Papillomavirus-Related Malignant N
Human Papillomavirus-Related Malignant Neoplasm
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
CAR-T engineering for colorectal cancer: integrating targets, tum
retroviral therapies suppress HIV replication but fail to eliminate integrated proviral DN
humanized mice, CD4-NBs significantly reduced plasma viremia
novel link between intracellular cholesterol metabolism and vascular growth
targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen
macrophages, we engineered a novel trispecific macrophage engager (TriME) designed for simultaneous engagement
payloads and remodel the tumor microenvironment; in infectious diseases, they enhance pathogen clearance; and in autoimmune dis
PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression
resistance to GA-DM, disruption of genes involved in ubiquitin-mediated proteolysis and the Hippo pathway sensitised cells to GA-DM
구조화 데이터
syngeneic murine model
mouse, mouse
PK
IC50 585
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.